Medical Condition & Diagnosis
Baby Sankalpo Das has been diagnosed with a serious pediatric cancer that requires prolonged and carefully monitored treatment under the Department of Paediatric Oncology at Tata Medical Center, Kolkata. As per the medical evaluation and patient summaries, his condition demands continuous chemotherapy cycles, supportive medications, and regular diagnostic investigations such as blood tests and infection monitoring. Children undergoing cancer treatment are extremely vulnerable to infections, fatigue, and complications related to low immunity. Sankalpo’s treatment plan includes scheduled chemotherapy sessions, hospital admissions, and follow-up reviews to ensure that his body responds safely to the medicines. Any interruption in treatment could put his life at serious risk. Doctors have clearly advised strict adherence to the treatment protocol for the best possible outcome.
Urgent Need for Support
Cancer treatment in children is a long and emotionally draining journey, especially for families with limited resources. Sankalpo’s parents are doing everything they can to save their child’s life, but without external support, continuing treatment will become impossible. Every chemotherapy session, every blood test, and every hospital visit is crucial for his recovery. Your support can help ensure uninterrupted treatment, timely medicines, and essential investigations. Even a small contribution can make a meaningful difference in this child’s fight against cancer. By extending your help, you are not just donating—you are giving Sankalpo a chance to grow, learn, and live a healthy future.
Family Background & Financial Hardship
Baby Sankalpo comes from a financially weak family residing in Sonarpur, South 24 Parganas, West Bengal. As reflected in the ration card and income documents, the family is dependent on government ration support and belongs to an economically disadvantaged background. The monthly income of the family is extremely limited and barely sufficient to meet basic household needs such as food, rent, and daily survival. With a child suffering from cancer, the financial pressure has multiplied many times. Travel expenses to Kolkata, medicine costs, investigations, and hospital-related charges have placed an unbearable burden on the family. Despite their best efforts, they are unable to manage these mounting expenses on their own.
Update 31 December 25 -
On 31st December 2025, Chemotherapy Cycle 6 (HD-VEC) was successfully administered to Baby Sankalpo Das as part of his treatment for Retinoblastoma (eye cancer). Along with chemotherapy, all required blood investigations were completed.
At present, Sankalpo is clinically stable, and doctors have observed no redness or watering in the affected eye, which is a positive sign in his response to treatment.
Ongoing Treatment Plan (Post 31st December 2025)
Following the completion of chemotherapy cycle 6, the next phase of treatment includes External Beam Radiotherapy (EBRT) to the orbit, including the optic chiasma.
Planned Radiotherapy Dose:
45 Gy in 25 fractions over 5 weeks
Doctors have also advised that further chemotherapy cycles will continue alongside radiotherapy, as per the oncology treatment protocol.
Upcoming Treatment & Monitoring Schedule
From 3rd January 2026 onwards:
G-CSF Injection (75 mcg, subcutaneous) to be given daily to support immunity until the next OPD visit.
7th January 2026:
Next Pediatric Oncology OPD visit scheduled, along with blood investigations (CBC with Differential) for review.
Baby Sankalpo remains under close medical supervision, and his treatment is progressing as planned under the guidance of the oncology team.
Update 5 January 2026 -
As part of his ongoing treatment for Retinoblastoma, daily G-CSF injections have been started for Baby Sankalpo Das from 3rd January 2026, at a dose of 75 mcg (subcutaneous), as advised by the treating doctors. These injections are being given to support his immunity during treatment.
Current Status – 5th January 2026
Baby Sankalpo is continuing with the daily G-CSF injections as planned. His condition is being closely monitored, and treatment is progressing as per medical advice.
Upcoming Medical Plan
7th January 2026:
The next Pediatric Oncology OPD visit is scheduled, along with CBC (Differential) blood tests.
Based on the investigation reports, a new treatment protocol will be initiated after 7th January 2026, as decided by the oncology team.
Baby Sankalpo remains under regular medical supervision as he continues his treatment journey.
Update 8 January 2026 -
Latest OPD Update – 7th January 2026
Baby Sankalpo Das was evaluated at Tata Medical Center, Kolkata, and his Pediatric Oncology OPD visit was completed on 07/01/2026. The oncology team reviewed his clinical condition in detail and updated his treatment plan based on the latest reports.
Current Clinical Status (07 January 2026)
Baby Sankalpo is clinically stable
Blood test results on 07/01/2026 showed:
Hemoglobin: 6.3 g/dL
Platelet count: 13,000
Due to low hemoglobin levels, an RBC transfusion of 270 ml was administered on 07/01/2026.
Additionally, supportive injections were given as advised by the doctors.
The parents have been strictly advised to monitor for fever and to follow all emergency precautions, as this phase of treatment remains sensitive.
Revised Treatment Protocol
As per the latest OPD assessment on 07/01/2026, Baby Sankalpo’s chemotherapy protocol has been revised.
He will receive two consecutive cycles of VEC chemotherapy
Further treatment decisions will be based on blood reports and overall clinical condition
Next Pediatric Oncology OPD visit: 14th January 2026
Investigations advised:
CBC with differential
Electrolytes
Renal profile
Baby Sankalpo continues to remain under close medical supervision, and his treatment is progressing as per the oncology team’s guidance.
All medical reports, hospital summaries, and treatment plans have been issued by Tata Medical Center, Kolkata.
This case is verified with hospital documentation. Daily survival itself is a challenge.
Cancer treatment cannot be delayed. Timely help ensures continuous care.